EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of RNA-binding protein RBMS3 as a potential biomarker for immunotherapy in bladder cancer

Tarimo Fredrick Praygod, Jinlong Li, Hongwei Li, Wanlong Tan, Zhiming Hu, Li Zhou

Cancer Biomarkers · 2024

DOI: 10.3233/cbm-230489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biomarkers, 2024. Verfasst von Tarimo Fredrick Praygod und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, RNA-Binding Proteins, Biomarkers, Tumor, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA-binding protein (RBP) plays pivotal roles in the malignant progression of cancer by regulating gene expression. In this paper, we aimed to develop RBP-based prognostic signature and identify critical hub RBPs in bladder cancer (BLCA). Firstly, a risk model based on differentially expressed RBP gens (DERBPs) between normal and tumor tissues was successfully established, which can predict the tumor stromal score and drug sensitivity. Then two another RBP risk models based on miRNA-correlated RBPs or lncRNA-correlated RBPs were also established, and RBMS3 was identified as the overlapping gene in the three models. Data from multiple bioinformatics databases revealed that RBMS3 was an independent prognostic factor for overall survival (OS), and was associated with an immunosuppressive tumor microenvironment (TME) in BLCA. Further, Single-cell RNA-Seq (scRNA-Seq) data and the human protein altas (HPA) database showed that RBMS3 expression (both mRNA and protein) were up-regulated in BLCA tumor and tumor stromal cells. Finally, RBMS3 was shown to be associated with worse response to BLCA immunotherapy. Overall, RBMS3 is a key prognostic RBP with TME remodeling function and may serve as a target for BLCA immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsRNA-Binding ProteinsBiomarkers, TumorImmunotherapyHumansPrognosisTumor MicroenvironmentGene Expression Regulation, NeoplasticFemaleMaleComputational Biology

Stichwörter der Autor:innen

RBMS3RNA-binding proteinbladder cancerimmunosuppressive tumor microenvironment

Substanzen

RNA-Binding ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Institute of Biotherapy, School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, Guangdong, China.
  • Institute of Interdisciplinary Research, Guangdong Polytechnic Normal University, Guangzhou, Guangdong, China.
  • Research Institute of Guangdong Polytechnic Normal University in Heyuan City, Guangdong, China.

Zitieren

APA

Praygod, T. F., Li, J., Li, H., Tan, W., Hu, Z., & Zhou, L. (2024). Identification of RNA-binding protein RBMS3 as a potential biomarker for immunotherapy in bladder cancer. Cancer Biomarkers. https://doi.org/10.3233/cbm-230489

Vancouver

Praygod TF, Li J, Li H, Tan W, Hu Z, Zhou L. Identification of RNA-binding protein RBMS3 as a potential biomarker for immunotherapy in bladder cancer. Cancer Biomarkers. 2024. doi:10.3233/cbm-230489

BibTeX
@article{Praygod2024,
  author = {Praygod, Tarimo Fredrick and Li, Jinlong and Li, Hongwei and Tan, Wanlong and Hu, Zhiming and Zhou, Li},
  title = {Identification of RNA-binding protein RBMS3 as a potential biomarker for immunotherapy in bladder cancer},
  journal = {Cancer Biomarkers},
  year = {2024},
  doi = {10.3233/cbm-230489}
}
Kostenlos starten →